EZZ Life Science Holdings Limited reported a gross profit of 18.2 million AUD for the half-year ending 31 December 2025 and a loss after income tax of 641,298 AUD. The company's revenue declined to 24.8 million AUD from 30.3 million AUD at the end of 2024, primarily due to reduced consumer demand in China and heightened competition. Despite this, sales in Australia and New Zealand increased significantly, and EZZ launched several new health supplements, continuing its focus on product innovation. The company maintained a strong cash position and remained debt-free. Strategic decisions included foregoing a potential merger to maintain financial stability and leveraging partnerships such as with the Australian Open to bolster brand visibility.
Key Points
EZZ Life Science Holdings Limited reported a gross profit of 18.2 million AUD for the half-year ending 31 December 2025.
The company experienced a loss after income tax of 641,298 AUD for the same period.
Revenue decreased to 24.8 million AUD from 30.3 million AUD at the end of 2024, due to softer consumer demand in China and increased price competition.
Sales in Australia and New Zealand increased by 25.8% to 5.4 million AUD.
EZZ launched three new health supplements during the financial half-year: EZZ Breast Health Capsule, EZZ Women’s Bone Strength Capsule, and EZZ R-21 Ergothioeine Capsule.
The company maintains a strong cash position of 13.5 million AUD and remains debt-free, allowing for financial flexibility.
The board decided against a potential merger and acquisition opportunity to prioritize balance sheet strength.
EZZ continued its partnership with the Australian Open to enhance brand visibility.
The company incurred non-cash share-based payment expenses of 1.3 million AUD related to Employee Share Schemes.
Basic earnings per share were reported at negative 1.36 cents.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.